Quarterly report pursuant to Section 13 or 15(d)

Note 14 - Subsequent Events

Note 14 - Subsequent Events
9 Months Ended
Mar. 31, 2021
Notes to Financial Statements  
Subsequent Events [Text Block]

Note 14. Subsequent Events:


On April 6, 2021, the Company acquired Asuragen, Inc. for approximately $215 million, plus contingent consideration of up to $105 million upon the achievement of certain future milestones.


On April 2, 2021, the Company invested approximately $6 million of additional funding into Eminence, increasing our percentage of outstanding equity shares to 57.42%.